It is the goal of the people behind Oncotarget to make any information about cancer and oncology, for that matter, available to the public. They are continually publishing news about the field of Oncology every week because they believe that everyone, included those not in the medical or scientific profession, deserve to know everything about cancer and the works medical experts do to prevent or treat it.

Cancer has taken the lives of so many fathers, mothers, and children, with the many varieties of the disease that exist and haunt the lives of different communities around the world. Oncotarget believes that it is in the best interest of people, from various nations and cultures, to have an open-access information hub on cancer research. This is not only aimed at helping people that are not in the medical industry, but also targeting those other researchers looking to expand their knowledge on the subject matter and ordinary people that want to be aware of new findings in the field of Oncology. Follow Oncotarget on Twitter.

Oncotarget is a peer-reviewed free online journal that publishes two issues per week, a rate that they have improved from the regular schedule of one topic per week, before the website got very popular.

The group started in 2010, with Mikhail Blagosklonny and Andrei V. Gudkov as the leading editors of the website, those who choose the topics and the publishments of that week.

Oncotarget is serious about making all the information, peer-reviewed, clinical studies/trials, and publications in everything related to oncology, open to the public that they also now have a podcast discussing oncology available in Player.FM, iTunes, and Stitcher. Apart from the reviews on the topic of Oncotarget, there are partitions of the website that focus on other types of researches as well.

Oncotarget’s editors-in-chiefs Mikhail Blagosklonny and the doctor Andrei V. Gudkov themselves made incredible contributions to the fight against cancer and made great leaps towards the development of oncology. Dr. Andrei V. Gudkov is known throughout the medical and scientific community for his work in DNA damage and repair, thermal and hypoxic stress and immune modulation, and photodynamic therapy.

Learn more: https://www.ncbi.nlm.nih.gov/pmc/journals/1558/

Mikhail Blagosklonny, on the other hand, is notable for his research on the wonder drug called Rapamycin which is also the main drug used to treat lymphangioleiomyomatosis or LAM. It is also used to prevent cancer from spreading throughout the body for its anti-proliferative effects. Rapamycin is also used as an immunosuppressant during organ transplant surgeries. Listen to an audio podcast of Oncotarget on Itunes.